MET and hepatocellular carcinoma: Also, several clinical trials are (Garcia-Vilas and Medina, 2018) being carried out in HCC patients using c-Met inhibitors (Table 1), including cabozanitinib, foretinib, cobazitinib, gefitinib, crizotinib, MSC2156119, AZD4547, MK2461, and INC280 (Schiffer et al., 2005; Goyal et al., 2013; Bladt et al., 2014; Sun et al., 2017; Garcia-Vilas and Medina, 2018).